Slides
Page 1
Siegfried to acquire high- quality small molecules drug substance capacity in the US Zofingen, January 2026
Page 2
|2 This presentation may contain confidential and proprietary information. Any use of the presentation or the information therein without specific permission of Siegfried is prohibited. No representations or warranties of any kind are made with regard to the accuracy or completeness of the information provided in or in connection with this presentation. Any statements, estimates and projections with respect to Siegfried’s anticipated future business or performance were prepared based on assumptions and information available at the time this presentation was prepared. Siegfried does not assume any liability or responsibility for actions or decisions of third parties based on this presentation. Disclaimer
Page 3
|3 − Siegfried signed binding agreements to acquire small molecules drug substances sites in the US and Australia − Transaction adds highly demanded US-based manufacturing capacity and strengthens Siegfried’s position in key growth segments − Given Siegfried’s strong balance sheet, the acquisition will be financed through existing and new debt instruments − Value accretive acquisition advances EVOLVE+ strategy and supports long-term profitable growth in the largest pharmaceutical market Siegfried to acquire high-quality small molecules drug substance capacity in the US Another Siegfried deal: Compelling manufacturing capacity at an attractive price
Page 4
|4 Significant demand from small and large pharma companies for manufacturing capacity for innovative products Structurally high demand meets limited US capacities Increasing number of innovations from small and mid-size pharma Increasing complexity of new molecular entities Ongoing outsourcing trend in the pharma industry Increased cost awareness in the pharma industry EVOLVE+ Demand push – Re-shoring and supply chain resilience initiatives – Largest pharma market with sustained growth – Small/mid-size pharma with limited in-house capacity Structural bottleneck in US-based CDMO capacity Constrained supply – Less than 15 large-scale chemical CDMO sites in US – Greenfield expansions take a long time
Page 5
|5 Acquired business includes three high-quality drug substances sites Noramco – Wilmington, DE (US) Extractas Bioscience – Tasmania, (AU) Purisys – Athens, GA (US) – Focused on three product families – Addiction treatment and prevention – ADHD – Pain management – Approx. 185 FTEs – CDMO facility for product development, clinical and small-scale manufacturing – Focused on highly regulated compounds and niche products – Approx. 45 FTEs – Leading manufacturer of purified products – Approx. 170 FTEs Backward integration increases resilience of supply chain Complementary to Grafton, further expands Acceleration Hub High-quality, multi-purpose site with 150m3 reactor capacity A perfect fit into our existing global network
Page 6
|6 Wilmington and Pennsville – Complementary pharma manufacturing cluster due to proximity and product portfolio – Controlled substances footprint to be optimized across the two sites – Wilmington to be repurposed for innovative products Athens and Grafton – To form best-in-class Acceleration Hub – Comprehensive offering for early phase development – Filling the pipeline for innovative products Acquisition significantly strengthens our footprint in the US Exceptional US-based capacity further enhances our customer offering Comprehensive drug substances offering US footprint passes critical size: 5 sites and 700 employees Irvine Athens Pennsville WilmingtonGrafton
Page 7
|7 7 | Attractive valuation, well below recent expectations for US assets Continuation of our highly selective, disciplined and value-accretive M&A Paving the way for continued, long-term profitable growth across all levels 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Siegfried trading multiple Seller expectations for US assets Implied EV/EBITDA of the acquired business Transaction – Valuation of acquired business is below 10 times Enterprise Value / EBITDA, below our own trading multiple and substantially below seller expectations of trading multiples of other US based assets – Acquired business will not be dilutive to existing business – Subject to customary closing conditions, we expect a closing later in the year – Given Siegfried’s strong balance sheet, the acquisition will be financed through existing and new debt instruments Valuation (EV/EBITDA)
Page 8
|8 Transaction further accelerates profitable growth A decisive step in the execution of our strategy EVOLVE+ Commercial Excellence Development Excellence Operational Excellence Enter and grow new areas Cell & gene therapy (CGT) DS antibodies Data analytics Grow existing core Aseptic liquid dosage forms Oral/inhalation solid dosage forms Grow the network in US and Europe End-to-end offering of DS and DP Small molecules (DS and DP) Broaden our technological offering Advanced production technologies Bridging technologies Viral vectors Synthetic biology Aseptic technologies EVOLVE+
Page 9
Thank you for your attention